Vesugen (KED, T-38): Khavinson Vascular Bioregulator Guide#

Vesugen is a synthetic tripeptide bioregulator with the sequence Lys-Glu-Asp (KED), designated T-38 in the Khavinson program, developed by the St. Petersburg Institute of Bioregulation and Gerontology and proposed to act as a vascular-endothelial tissue-selective gene regulator (Khavinson V, Ilina A, Kraskovskaya N, et al. Pharmaceuticals 2021; PMID 34071923; DOI: 10.3390/ph14060515)¹. Last verified June 4, 2026.

What is Vesugen?#

Vesugen is a synthetic tripeptide composed of three amino acids -- lysine, glutamic acid, and aspartic acid (Lys-Glu-Asp), abbreviated KED. Within the Khavinson research program it carries the internal designation T-38. The peptide has a molecular weight of approximately 390 Da, the molecular formula C15H26N4O8, and a free-amine N-terminus / free-carboxylate C-terminus.

Vesugen belongs to the Khavinson family of short-peptide bioregulators, alongside Epitalon (AEDG, pineal), Pinealon (EDR, neural), Vilon (KE, thymus), Thymalin (thymus complex), and Prostamax (KEDP, prostate). Within this framework, Vesugen is proposed as the bioregulator for vascular endothelium, with reported effects on SIRT1 expression and Ki-67 proliferation marker dynamics in endothelial cell culture and aged-rat tissue.

The strongest verifiable PubMed-indexed citation for Vesugen is Khavinson V, Ilina A, Kraskovskaya N, et al., Pharmaceuticals 2021 (PMID 34071923; DOI: 10.3390/ph14060515)¹. In that study, KED is co-tested with EDR (Pinealon) in a 5xFAD mouse model of Alzheimer's disease. KED at 400 mcg/kg/day intraperitoneal injection from 2 to 4 months of age was reported to prevent dendritic spine loss and to trend toward increased neuroplasticity markers. The same paper reports in-silico molecular docking predicting KED binding to promoter regions of AD-relevant genes including CASP3, NES, GAP43, APOE, SOD2, PPARA, and PPARG -- a computational result, not a direct biophysical confirmation.

Vesugen is not an FDA-approved drug, not a prescription product in any Western jurisdiction, and not an independently validated SIRT1 activator in the sense that resveratrol or NAD-boosting therapies are studied. Most of the SIRT1- and Ki-67-related claims come from Russian-language Khavinson-program reports.

Mechanism of Action#

Proposed Tissue-Selective Bioregulation#

Within the Khavinson framework, Vesugen is proposed as a vascular-endothelial gene regulator that:

• Modulates expression of SIRT1 (sirtuin-1, a NAD-dependent deacetylase implicated in vascular aging)
• Modulates expression of Ki-67 (a proliferation marker), with reported normalisation toward younger phenotypes
• Restores endothelial function in aged-rat vascular tissue

The PMID 34071923 paper extends this to the central nervous system: KED is shown to preserve dendritic spine density in the 5xFAD Alzheimer's mouse model, with molecular-docking predictions of binding to AD-relevant gene promoters (APOE, SOD2, CASP3, GAP43, NES, PPARA, PPARG)¹. The docking predictions are computational and have not been confirmed by structural biology in the same paper.

Proposed SIRT1 Pathway Linkage#

The Khavinson-program SIRT1 linkage proposes that KED-induced SIRT1 expression in endothelial cells contributes to age-related vascular gene-expression normalisation. SIRT1 is a well-studied target in vascular biology -- elevated SIRT1 activity is associated with improved endothelial function, vasodilation, and reduced senescence -- so the biological framing is plausible. However:

• Independent PubMed-indexed confirmation of KED → SIRT1 induction outside the Khavinson program is limited
• The proposed direct peptide-DNA binding mechanism remains unconfirmed by structural biology
• Alternative mechanisms (e.g., indirect effects via cell-surface receptors, antioxidant activity, immunomodulation) have not been rigorously explored

Mechanistic Plausibility Concerns#

The proposed mechanism -- a free three-amino-acid peptide (390 Da) reaching cell nuclei and binding DNA with sequence specificity -- faces the same theoretical challenges raised for other Khavinson short peptides. Classical sequence-specific DNA-binding proteins rely on extensive tertiary structure (zinc fingers, helix-turn-helix, leucine zippers); a tripeptide lacks the structural complexity normally required for selective DNA recognition. The molecular-docking studies in PMID 34071923 are in-silico predictions, not direct binding measurements.

Therapeutic Claims and Evidence Base#

Vascular Aging Models#

Russian-language reports from the Khavinson group describe Vesugen administration to aged-rat models with readouts including endothelial function, SIRT1 immunohistochemistry, and Ki-67 staining of vascular tissue. These reports are largely not PubMed-indexed and have not been independently replicated.

Neurological / Alzheimer's Model#

The PMID 34071923 5xFAD study is the strongest published Vesugen-related evidence and demonstrates dendritic spine preservation in an Alzheimer's mouse model. Notably, KED is co-administered with EDR (Pinealon) for most endpoints, which complicates attribution of effects specifically to KED¹.

What Vesugen Is Not#

• Not FDA, EMA, MHRA, or Health Canada-approved for any indication
• Not the same as Pinealon (EDR) even though it is co-tested with Pinealon in PMID 34071923
• Not a validated SIRT1 activator in the sense of resveratrol or NAD precursors -- the SIRT1 linkage rests largely on Khavinson-program reports
• Not a substitute for evidence-based cardiovascular prevention (statins, blood-pressure control, lifestyle, aspirin where indicated)

Important Considerations#

• Vesugen (KED, T-38) is a research compound, not an approved medicine in any Western regulatory jurisdiction
• The strongest PubMed-indexed citation (PMID 34071923) is a mouse Alzheimer's model with co-administration of EDR
• The proposed vascular SIRT1/Ki-67 mechanism rests largely on Russian-language Khavinson-program reports
• Material sold as Vesugen is not subject to pharmaceutical manufacturing standards; purity and identity are not guaranteed
• Cardiovascular concerns should be evaluated by a clinician with evidence-based therapy as the first-line option

Key Research Findings#

Neuroprotective Effects of Tripeptides -- Epigenetic Regulators in Mouse Model of Alzheimer's Disease, published in Pharmaceuticals (Khavinson V, Ilina A, Kraskovskaya N, et al., 2021; PMID 34071923; DOI: 10.3390/ph14060515):

• KED (Vesugen) 400 mcg/kg/day IP from 2-4 months prevented dendritic spine loss in 5xFAD mice
• Molecular-docking predictions for KED binding to APOE, SOD2, CASP3, GAP43, NES, PPARA, PPARG promoters
• KED was co-tested with EDR (Pinealon) for most endpoints, complicating attribution

References#

Related Reading#

• Vesugen research studies and evidence
• Vesugen dosing protocols
• Vesugen side effects profile
• Pinealon research guide
• Epitalon research guide
• Prostamax (KEDP) research guide
• Vilon research guide
• Thymalin research guide

Footnotes#

1. Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M. Neuroprotective Effects of Tripeptides -- Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals. 2021. PMID: 34071923. DOI: 10.3390/ph14060515. ↩ ↩² ↩³ ↩⁴